Jump to content

Polymyxin: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Arcadian (talk | contribs)
nav
No edit summary
Line 1: Line 1:
'''Polymyxins''' are [[antibiotic]]s, with a general structure of a cyclic
'''Polymyxins''' are [[cationic]] [[detergent]] [[antibiotic]]s, with a general structure of a cyclic [[peptide]] with a long [[hydrophobic]] tail. They disrupt the structure of the bacterial cell membrane by interacting with its [[phospholipid]]s. Polymyxins have a bactericidal effect on [[Gram-negative]] [[bacilli]], especially on ''[[Pseudomonas]]'' and [[coliform]] organisms. Polymyxin antibiotics are highly [[neurotoxic]] and [[nephrotoxic]], and very poorly absorbed from the gastrointestinal tract. Polymyxins also have antifungal activity.
[[peptide]] with a long [[hydrophobic]] tail. They disrupt the structure of the
bacterial cell membrane by interacting with its [[phospholipid]]s. They are
produced by the Gram-positive bacterium ''Bacillus polymyxa'' and are
selectively toxic for Gram-negative bacteria due to their specificity for
[[lipopolysaccharide]] in the outer membrane of the cell wall of these
organisms.


Polymyxins [[B|Polymyxin B]] and E (also known as [[colistin]]) are used in the
Well known examples:
treatment of infections with gram-negative bacteria.


== Mode of action ==
* [[Colistin]]
After binding to lipopolysaccharide (LPS) in the outer membrane of Gram-negative
* [[Polymyxin B]]
bacteria, polymyxins disrupt both the outer and inner membrane. The hydrophobic
* [[Surfactin]]
tail is important in causing membrane damage, suggesting a [[detergent]]-like
mode of action.

Removal of the hydrophobic tail of polymyxin B yields [[polymyxin nonapeptide]],
which still binds to LPS but does no longer kill the bacterial cell. However, it
still detectably increases the permeability of the bacterial cell wall to other
antibiotics, indicating that it still causes some degree of membrane
disorganization.

Gram-negative bacteria can develop resistance to polymyxins through various
modifications of the LPS structure that inhibit the binding of polymyxins to
LPS.

== Clinical use ==

Polymyxin antibiotics are considered relatively [[neurotoxic]] and [[nephrotoxic]] and, though effective, are therefore used only if less toxic antibiotics cannot. Typical use cases are infections with strains of
''[[Pseudomonas aeroginosa]]'' or [[Enterobacteriaceae]] species that are highly resistant to other types of antibiotics such as [[cephalosporins]].

Polymyxins are not absorbed from the gastrointestinal tract and therefore have to be applied intravenously.


Polymyxin acts as an antibiotic by damaging the cytoplasmic membrane of bacteria.
Also polymyxins biological source is Bacillius polymyxa.
== See also ==
== See also ==
* [[Polysporin]]
* [[Polysporin]]




==References==
==References==
{{cite journal
| author = Tran AX, Lester ME, Stead CM, Raetz CR, Maskell DJ, McGrath SC, Cotter RJ, Trent MS.
| title = Resistance to the antimicrobial peptide polymyxin requires myristoylation of Escherichia coli and Salmonella typhimurium lipid A.
| journal = J. Biol. Chem.
| volume = 280
| pages = 28186-94
| year = 2005
| pmid = 15951433
}}

{{cite journal
| author = Dixon R.A., Chopra I.
| title = Polymyxin B and polymyxin B nonapeptide alter cytoplasmic membrane permeability in Escherichia coli.
| journal = J. Antimicrob. Chemother.
| volume = 5
| pages = 557-563
| year = 1986
| pmid = 3027012
}}

{{cite journal
{{cite journal
| author = Falagas ME, Kasiakou SK
| author = Falagas ME, Kasiakou SK
Line 25: Line 71:
| url = http://ccforum.com/content/10/1/R27
| url = http://ccforum.com/content/10/1/R27
}}
}}



==External links==
==External links==

Revision as of 14:35, 28 March 2008

Polymyxins are antibiotics, with a general structure of a cyclic peptide with a long hydrophobic tail. They disrupt the structure of the bacterial cell membrane by interacting with its phospholipids. They are produced by the Gram-positive bacterium Bacillus polymyxa and are selectively toxic for Gram-negative bacteria due to their specificity for lipopolysaccharide in the outer membrane of the cell wall of these organisms.

Polymyxins Polymyxin B and E (also known as colistin) are used in the treatment of infections with gram-negative bacteria.

Mode of action

After binding to lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, polymyxins disrupt both the outer and inner membrane. The hydrophobic tail is important in causing membrane damage, suggesting a detergent-like mode of action.

Removal of the hydrophobic tail of polymyxin B yields polymyxin nonapeptide, which still binds to LPS but does no longer kill the bacterial cell. However, it still detectably increases the permeability of the bacterial cell wall to other antibiotics, indicating that it still causes some degree of membrane disorganization.

Gram-negative bacteria can develop resistance to polymyxins through various modifications of the LPS structure that inhibit the binding of polymyxins to LPS.

Clinical use

Polymyxin antibiotics are considered relatively neurotoxic and nephrotoxic and, though effective, are therefore used only if less toxic antibiotics cannot. Typical use cases are infections with strains of Pseudomonas aeroginosa or Enterobacteriaceae species that are highly resistant to other types of antibiotics such as cephalosporins.

Polymyxins are not absorbed from the gastrointestinal tract and therefore have to be applied intravenously.

See also


References

Tran AX, Lester ME, Stead CM, Raetz CR, Maskell DJ, McGrath SC, Cotter RJ, Trent MS. (2005). "Resistance to the antimicrobial peptide polymyxin requires myristoylation of Escherichia coli and Salmonella typhimurium lipid A.". J. Biol. Chem. 280: 28186–94. PMID 15951433.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Dixon R.A., Chopra I. (1986). "Polymyxin B and polymyxin B nonapeptide alter cytoplasmic membrane permeability in Escherichia coli". J. Antimicrob. Chemother. 5: 557–563. PMID 3027012.

Falagas ME, Kasiakou SK (2006). "Toxicity of polymyxins: a systematic review of the evidence from old and recent studies". Crit Care. 10 (1): R27. doi:10.1186/cc3995. PMID 16507149.{{cite journal}}: CS1 maint: unflagged free DOI (link)